上海醫藥(02607.HK)將SPH6162海外權益許可給HUYABIO
格隆匯10月28日丨上海醫藥(02607.HK)發佈公吿，近日， 公司與HUYABIO INTERNATIONAL LLC達成一項獨家許可協議，以不超過2.925億美元（除銷售提成外）的交易金額將具有自主知識產權的SPH6162在中國區域（包括香港、澳門及台灣，下同）以外的製造、使用、銷售、進口、開發及商業化權利有償獨家許可給HUYABIO，SPH6162在中國區域的有關權益仍歸上海醫藥所有。
SPH6162為上海醫藥中央研究院自主研發的抗腫瘤小分子抑制劑；通過抑制激酶活性，抑制腫瘤細胞對藥物的損傷修復，從而達到對腫瘤細胞殺傷。SPH6162目前處於臨牀前開發階段，已提交兩款化合物的國際專利申請。截至本公吿日，全球尚無同靶點的藥物獲批上市。
據悉，HUYABIO成立於2004年，總部位於美國聖地亞哥，是一家立足於商業模式創新的國際化新藥開發的美國公司。HUYABIO旨在從中國的研究機構與製藥公司尋求原創且具有開發前景的臨牀前以及臨牀階段創新產品，通過其在海外積累的臨牀開發資源和能力，為中國創新藥提供國際化開發和通往全球醫藥市場的橋樑。
公司表示，SPH6162的海外授權進一步證實了上海醫藥的研發實力，有利於提高上海醫藥的國際影響力。SPH6162 為全球同靶點研發快速跟進產品，藉助海外合作伙伴的資源和研發力量，有望加快該產品在國內外的同步開發速度。通過與海外藥企的合作，進一步探索海外臨牀試驗的開發以及上市路徑，為公司後續創新產品的出海奠定了基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
